These are all very high ranking former Merck executives -- and now, Inovio is poised to seek FDA approval for its first DNA medicine -- INO-3107, a potential recurrent respiratory papillomatosis treatment that it plans to submit for FDA approval this year. In the bio-sciences, the path to market is often a multi decade affair. And this is Exhibit A, for that idea [as we've been watching -- as an investor, since about late August, of 2012]. Here's to wishing all these Merck alums. . . all the best:
. . .[Inovio has replaced 2021 hire Mark] Twyman [who] discussed preparations to launch INO-3107 on an Inovio earnings call in May. Seven weeks later, Inovio revealed the appointment of Egge as chief commercial officer. The statement about the new hire makes no mention of Twyman. . . .
Egge arrives as Inovio, a biotech founded at the start of the century, prepares to become a commercial company. Inovio CEO Jacqueline Shea discussed the preparations at an investor event in May, telling the attendees that “commercialization plans are well underway” and multiple work streams are on the go.
“We're really working to understand both the healthcare provider and the patient landscape,” Shea said. “We've been doing some claims database analysis to really understand where those patients are, which physicians they go to, so that we can really target our field force appropriately. . . .”
Now you know. Have a safe and happy one, one and all!
नमस्ते
No comments:
Post a Comment